Schrodinger Inc stock (US80655G1067): shares extend late-May rebound on Nasdaq
02.06.2026 - 05:49:13 | ad-hoc-news.de
Schrodinger Inc shares on the Nasdaq Global Select Market held near the mid-teens on 06/02/2026, consolidating gains after the United States-based stock logged an intraday rise of about 7.3% to an intraday high of USD 15.43 on 05/29/2026, according to a report from MarketsMojo as of 05/29/2026 and Nasdaq price data as of 05/29/2026.MarketsMojo as of 05/29/2026Nasdaq as of 05/29/2026
The software-enabled drug discovery group, headquartered in the United States and listed under ticker SDGR on Nasdaq, saw its stock gain roughly 14.3% over the week and about 29.3% over the month ended 05/29/2026, again per MarketsMojo, reflecting renewed interest in the name within the US growth and biotech software segment.MarketsMojo as of 05/29/2026
The stock traded at USD 15.20 on 05/29/2026 on Nasdaq, according to Investing.com data as of 05/29/2026, underscoring that the recent swing has taken place squarely on the companys home US exchange, which often serves as the primary liquidity venue for Schrodinger.Investing.com as of 05/29/2026
As of: 02.06.2026
By the editorial team - specialized in equity coverage.
At a glance
- Name: SDGR
- Sector/industry: Computational drug discovery software and biotechnology
- Headquarters/country: New York, United States
- Core markets: North America, Europe, Asia-Pacific
- Key revenue drivers: Software licenses and subscriptions for molecular modeling, drug discovery collaborations, and milestone and royalty income from partnered pipelines
- Home exchange/listing venue: Nasdaq Global Select Market (SDGR)
- Trading currency: USD
Schrodinger Inc: core business model
Schrodinger focuses on applying physics-based computational platforms to streamline pharmaceutical and biotechnology research while generating revenue through software licensing and co-discovery partnerships that can yield milestones and potential royalties.
Latest quarterly results for Schrodinger Inc at a glance
For the quarter ended 03/31/2026, Schrodinger reported its latest set of results via a press release filed on the investor relations section of its website on 05/08/2026, which detailed performance across its software and drug discovery segments, according to the companys investor relations materials as of 05/08/2026.Schrodinger IR as of 05/08/2026
The filing outlined quarterly revenue split between recurring software business and collaboration-driven discovery income, allowing investors to gauge how the recent share-price move on Nasdaq lines up with fundamentals from the United States-based group in early 2026, as presented in the 05/08/2026 communication.Schrodinger IR as of 05/08/2026
Read more
Additional news and developments on the stock can be explored via the linked overview pages.
Sentiment and reactions on Schrodinger Inc
The late-May swing in Schrodinger Incs share price and its role in computational drug discovery are likely to feature in discussions across social and video platforms as market participants assess the United States-listed stock.
Conclusion
The recent move in Schrodinger Incs share price on Nasdaq, highlighted by the 05/29/2026 intraday jump and the stocks performance over the past week and month, has drawn fresh focus to this United States-based name in the computational drug discovery space.
With the most recent quarterly figures from 03/31/2026 disclosed on 05/08/2026, investors can compare the momentum in the trading price with the companys reported split between software and discovery revenues as they monitor how the story develops from here.
Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.
